Targeting the vasopressin type-2 receptor for renal cell carcinoma therapy.
Sinha S, Dwivedi N, Tao S, Jamadar A, Kakade VR, Neil MO, Weiss RH, Enders J, Calvet JP, Thomas SM, Rao R.
Sinha S, et al. Among authors: rao r.
Oncogene. 2020 Feb;39(6):1231-1245. doi: 10.1038/s41388-019-1059-0. Epub 2019 Oct 15.
Oncogene. 2020.
PMID: 31616061
Free PMC article.